Navigation Links
EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
Date:4/9/2008

Phase 1 study marks the achievement of a critical milestone in our clinical development program and further supports our strategy of focusing on orally-administered, small molecule drugs with multiple mechanisms of action. Data from preclinical studies with ENMD-2076 demonstrate its significant antitumor potential as a single agent in a variety of tumor types. Through this Phase 1 study, we expect to not only determine ENMD-2076's safety profile and appropriate Phase 2 dosing schedule, but which tumor types may be better suited for this compound. We plan to initiate a second Phase 1 study in patients with hematological cancers later this year."

James S. Burns, EntreMed President & Chief Executive Officer commented, "ENMD-2076 is an exciting selective kinase inhibitor with potent single agent activity that has induced tumor regression in multiple preclinical models. ENMD-2076, developed internally, is consistent with our focus on investing behind oncology drug candidates with strong single-agent activity and with our continuing interest in selective kinase inhibitors. In parallel with the clinical trial, we will seek a pharmaceutical or biotech partner to help accelerate the development of our novel selective kinase inhibitor."

The administration of ENMD-2076 to the first patient in this important Phase 1 study will trigger a milestone payment by EntreMed pursuant to EntreMed's acquisition of Miikana Therapeutics, Inc. in January 2006. Under the terms of the merger agreement with Miikana, the dosing of the first patient triggers a $2 million payment to the former Miikana stockholders, either in cash or shares of EntreMed common stock.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is an oral cell-cycle regulator with activity against the mTOR pathway. EN
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. EntreMed Commences Continuous Dosing Clinical Trial For MKC-1
2. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
3. EntreMed to Present at The New York Society of Security Analysts Industry Conference
4. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
5. EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
6. EntreMed Reports Phase 1 PK and Preclinical Efficacy Results for ENMD-1198
7. EntreMed Raises $20 Million to Support Clinical Development Program
8. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
9. Bionomics Achieves US$1 Million Milestone Payment from Genmab
10. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
11. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... , Oct. 2, 2014  MinuteClinic, the largest and fastest growing ... , has opened its first walk-in clinics in the ... in Corpus Christi and Portland ... Christi in December. The clinics are part ... in 2014. With the Corpus Christi -area openings, ...
(Date:10/2/2014)... Ireland , Oct. 2, 2014   West ... a global leader in innovative solutions for injectable drug ... manufacturing operations to include a new site in ... produce packaging components for insulin injector cartridges and other ... from pharmaceutical and biotech customers. Once operational, this new ...
(Date:10/1/2014)... BOSTON , Oct. 1, 2014   ... market-leading provider of Anesthesia Information Management Systems (AIMS), ... Systems, LLC , a wholly owned subsidiary of ... healthcare information systems and connectivity solutions.  ... http://photos.prnewswire.com/prnh/20140930/149407 This partnership ...
Breaking Medicine Technology:First MinuteClinic Walk-in Medical Clinics Open in Corpus Christi 2First MinuteClinic Walk-in Medical Clinics Open in Corpus Christi 3West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 2West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 3West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 4West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 5Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 2Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 3
... CORAL SPRINGS, Fla., Jan. 27, 2011 Boca ... and Drug Administration (FDA) approval and commercial launch ... 10mg/300mg) Boca,s generic version of Victory Pharma,s Xodol®. ... relief of moderate to moderately severe pain ...
... Inc. (OTC Bulletin Board: LTUSD) ("Lotus" or the "Company"), ... and drugs in the People,s Republic of China ("PRC"), ... the Company has obtained land price guidance from the ... provide additional details regarding its 2008 purchase of land ...
Cached Medicine Technology:Lotus Pharmaceuticals Provides Inner Mongolia Land Price Guidance from Cha You Qian Qi Government 2
(Date:10/2/2014)... 2014 Recently, BambooIndustry.com, a professional company ... collection of bamboo floors . What’s more, the ... of its products at the moment. According to the ... 26 percent off. The promotion will be valid until ... http://www.bambooindustry.com ) are all made by qualified workers. A ...
(Date:10/2/2014)... October 02, 2014 BamboofloorChina.com is a ... products have won great appreciation from the global customers ... working hard to make more excellent items. All its ... to help all clients. , The company has ... to its website. Furthermore, the company’s marketing specialist ...
(Date:10/2/2014)... Oct. 1, 2014 (HealthDay News) -- Children with autism ... they,re fully capable of being more active, a small ... levels of 29 children, some with autism and some ... day of moderate physical activity and 70 more minutes ... 17 children with autism scored lower on strength, but ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, ... Columbia now have a total of 500 confirmed cases of ... children since the summer, U.S. health officials reported Wednesday. ... recent weeks, but it,s not clear what role -- if ... Health officials are also trying to determine if the ...
(Date:10/1/2014)... research study published today in the Journal of ... older than 50 years with moderate or severe chronic ... Researchers from the University of Melbourne randomly assigned 282 ... to no acupuncture or sham or pretend laser treatment. ... participants and acupuncturists blinded to laser and sham (inactive) ...
Breaking Medicine News(10 mins):Health News:BambooIndustry.com: Great Bamboo Floors At Discounted Rates 2Health News:High Quality Bamboo Panels Online At BamboofloorChina.com 2Health News:Kids With Autism Tend to Be Less Active, Study Says 2Health News:42 States Reporting Respiratory Virus That Targets Kids 2Health News:42 States Reporting Respiratory Virus That Targets Kids 3Health News:Study finds acupuncture does not improve chronic knee pain 2
... , CHARLESTON, W.Va., Dec. 4 UniCare ... and West Virginia Radio Corporation will be holding the ... Mission. Several local celebrities, including 2006 World,s Strongest Man ... State Natalie Tenant, and Governor and Mrs. Manchin will ...
... ... an information technology (IT) and web products and services provider for ... -hospital web sites earned ten awards in the Strategic Communications ... Solutions Executive Director of web products and services, Chris Catallo, at ...
... been made over the last 15 years in the healthcare ... Yet this progress in epilepsy management has not reached ... many of the nearly three million people in the United ... Schachter, M.D., president of the American Epilepsy Society (AES), there ...
... first indication they understand what 2-D images represent, researchers ... can recognize photographs of other monkeys they know, proving ... figure out if they,ve seen them before, researchers report. ... decipher the two-dimensional nature of a photograph, the scientists ...
... LOS ANGELES, Dec. 4 Yogen Fruz , the world,s ... themed "NUmixes" -- Yog-Nog and Mint Chocolate Chip ... at Yogen Fruz stores across North America. Yogen Fruz,s low-calorie Yog-Nog ... alternative to indulge in this holiday season. , "We ...
... ... of novel and effective computational methods for drug discovery, has joined ... developing rare chemical trading platform and builds database of commercially available ... chemists at InhibOx where they incorporate it into the virtual screening ...
Cached Medicine News:Health News:UniCare, Walmart Organize Circle of Hope To Help Mountain Mission Meet Increased Demand for Assistance 2Health News:CareTech Solutions Web Clients Earn Top Recognition in the Tenth Annual eHealthcare Leadership Awards Competition 2Health News:CareTech Solutions Web Clients Earn Top Recognition in the Tenth Annual eHealthcare Leadership Awards Competition 3Health News:Epilepsy patients caught in treatment gap are not getting state-of-the-art care 2Health News:Epilepsy patients caught in treatment gap are not getting state-of-the-art care 3Health News:Epilepsy patients caught in treatment gap are not getting state-of-the-art care 4Health News:Yogen Fruz Introduces New Holiday Flavors: Yog-Nog and Mint Chocolate Chip 2Health News:InhibOx and Molport Join Forces to Deliver Integrated Lead Design and Delivery 2Health News:InhibOx and Molport Join Forces to Deliver Integrated Lead Design and Delivery 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: